Develops next-gen biologics using its proprietary Affimer® platform technology. It is based on a naturally occurring human protein, engineered to behave like an antibody, but smaller, simpler, more robust, easy to format, cheaper and quicker to produce, highly specific to the target and non-immunogenic. Lead assets are PD-L1/LAG-3 single molecule bispecific inhibitor and a PD-L1 tumour microenvironment targeted innate immune activators (I-DASH inhibitors, STING agonists). First-in-man data exp. in 2020. Partnerships with Moderna and OncoSec (Gene delivery), Memorial Sloan Kettering (CAR-T), Iksuda and Tufts University (Drug conjugates). Affimer reagents business for Dx and research.
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Upcoming Company Event Participation
European Biotech Investor Day 2019
New York City,
August 1, 2019
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by